Heparin Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Heparin Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Heparin is an anticoagulant used to decrease the clotting ability of blood and help to prevent harmful clots from forming in blood vessels. It is sometimes referred as a blood thinner, although it does not actually thin the blood. Heparin does not dissolve already formed blood clots, but it can prevent the clots from becoming larger and causing more serious problems. Pharmaceutical-grade heparin is derived from animal tissue. Heparin is commonly used in the treatment of coronary heart disease, pulmonary embolism, deep vein thrombosis, and atrial fibrillation, and in the prevention of thrombosis during extracorporeal membrane oxygenation and cardiopulmonary bypass.
Market Dynamics
Rising cases of conditions such as coronary heart disease, pulmonary embolism, and deep vein thrombosis is one of the major factors for increased demand of heparin drugs in the market. Myocardial infarction (MI) is one of the major complications of coronary heart disease. According to the American Heart Association 2018 report, coronary heart disease is the leading cause (43.8%) of deaths due to cardiovascular disease in the U.S., followed by stroke (16.8%). As per the Centres for Disease Control and Prevention (CDC) 2015 report, deep vein thrombosis affects nearly 900,000 individuals in the U.S. each year.
Despite major applications in chronic conditions, heparin is poorly absorbed by the intestine, therefore it must be given intravenously or subcutaneously. Moreover, the drug creates a significant risk of excessive bleeding due to anticlotting effect. Heparin also induce conditions such as thrombocytopenia (reduced number of circulating platelets) and hypersensitivity reactions. These factors can hamper the heparin market, during the forecast period.
Key features of the study:
This report provides in-depth analysis of the heparin market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global heparin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global heparin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for heparin market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Heparin Market, By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
Global Heparin Market, By Dosage Form:
Injection
Solutions
Global Heparin Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Africa
By Country:
South Africa
Central Africa
North Africa
By Product Type:
Unfractionated Heparin (UH)
Low Molecular Weight Heparin (LMWH)
Ultra-low Molecular Weight Heparin (ULMW)
By Dosage Form:
Injection
Solutions
Company Profiles
Anselm Pharmaceuticals*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Baxter International Inc.
B. Braun Melsungen AG
Bristol-Myers Squibb Co.
Dr. Reddy’s Laboratories Ltd.
Fresenius SE & Co. KGaA
Leap Labchem Co.
LEO Pharma A/S
Pfizer, Inc.
Sanofi S.A.
Syntex S.A.
Teva Pharmaceutical Industries Ltd.
United Biotech (P) Ltd.
“*” marked represents similar segmentation in other categories in the respective section.